Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mei Elsayed

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Pharmaceuticals (Basel, Switzerland)|January 26, 2021
Therapeutic Sequencing in ALK<sup>+</sup> NSCLCMei Elsayed, Petros Christopoulos
Frontiers in Oncology|May 7, 2021
Feasibility and Challenges for Sequential Treatments in ALK-Rearranged Non-Small-Cell Lung CancerMei Elsayed, Farastuk Bozorgmehr, Daniel Kazdal, et al.
International Journal of Cancer|January 25, 2018
EML4-ALK fusion variant V3 is a high-risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK<sup>+</sup> non-small cell lung cancerPetros Christopoulos, Volker Endris, Farastuk Bozorgmehr, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Pharmaceuticals (Basel, Switzerland)|January 26, 2021
Therapeutic Sequencing in ALK<sup>+</sup> NSCLCMei Elsayed, Petros Christopoulos
Frontiers in Oncology|May 7, 2021
Feasibility and Challenges for Sequential Treatments in ALK-Rearranged Non-Small-Cell Lung CancerMei Elsayed, Farastuk Bozorgmehr, Daniel Kazdal, et al.
International Journal of Cancer|January 25, 2018
EML4-ALK fusion variant V3 is a high-risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK<sup>+</sup> non-small cell lung cancerPetros Christopoulos, Volker Endris, Farastuk Bozorgmehr, et al.
Pageof 1